Fatty liver disease is caused by an accumulation of fat in the hepatocytes. Non Alcoholic Fatty Liver Disease (NAFLD) has been reported worldwide, estimated to be around 10–24% in various populations. There is no standard medical treatment specifically for “Non-alcoholic, non-Diabetic and non- obese Fatty liver Disease”, hence a preliminary clinical study has been conducted at RRIUM Chennai, to evaluate the safety and efficacy of the Unani coded drug UNIM-104 in the treatment of NAFLD. It was observed that there was reduction in the sign and symptoms at the end of trial with statistical improvement (p< 0.05) in Hounz field (HF) Units value on CT scan of liver.